SureTrader Advertisement PRTC
Home > Boards > Free Zone > Health and Sciences > Biotech Values

>AVEOwhether they would rather focus on other indications

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
biomaven0 Member Profile
Member Level 
Followed By 76
Posts 4,358
Boards Moderated 0
Alias Born 02/27/07
160x600 placeholder
U.S. Stocks Move Higher, Boosted By Oil's Gains
Jobless claims miss expectations; Alibaba climbs on strong earnings; Tesla, L Brands fall U.S. stocks were moving higher Thursday, on track...
Top Equities Stories Of The Day
Ackman: No Plans to Sell Any Valeant `Crown Jewel' Assets -CNBC
GM, Lyft to Test Self-Driving Electric Taxis
Cable Business Powers Fox Revenue Increase -- WSJ
Brazilian Judge Lifts WhatsApp Ban -- Update
Microsoft Aims to Wrangle Data for Office Teams With SharePoint Revamp
Pfizer Has Approached Medivation About Potential Acquisition -Reuters
Alibaba Profit, Revenue Increase -- Update
Mining Giants Hit by Brazil Suit -- WSJ
biomaven0 Member Level  Thursday, 09/08/11 09:41:43 AM
Re: NP1986 post# 126293
Post # of 201173 
>AVEO

Quote:
whether they would rather focus on other indications



My guess is they will try to go for combination therapy - any place where Avastin has shown good results in combination would be a good place to start.

In terms of going up against Sutent vs. against Nexavar, it's somewhat instructive that Pfizer made the same choice in 2nd line for their drug. I'm of the view that a small company should almost always take the easiest path to registration - worry about expanding the market once you have approval.

Peter

SureTrader
Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist